Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01864655 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability of AZD0530 (Saracatinib) in Alzheimer's Disease
A Phase 1 study of Alzheimers Disease, sponsored by Stephen M. Strittmatter.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT01864655: Completed Phase 1 study of Alzheimers Disease, sponsored by Stephen M. Strittmatter.
NCT01864655 is a Phase 1 study of Alzheimers Disease that has completed, run by Stephen M. Strittmatter. The registered enrollment target is 24 participants, below the 4,061-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01864655, a Phase 1 study of Alzheimers Disease, has completed, sponsored by Stephen M. Strittmatter.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
Alzheimer's disease is a devastating neurodegenerative disorder, for which there is currently no effective treatment to slow or halt progression. Beta amyloid peptide accumulates in the brains of those with Alzheimer's, and is thought to play a major role in triggering the dementia. The investigators recently characterized a molecular pathway by which ß-amyloid damages neurons, and showed that the protein termed Fyn kinase is crucial. Our data suggest that blocking Fyn will have a significant therapeutic benefit for Alzheimer's. Astra Zeneca has developed a blocker of Fyn and related kinases (AZD0530) for the treatment of cancer. Chronic AZD0530 administration is well tolerated in humans, and the investigators propose to test its potential as a novel Alzheimer's disease modifying therapy. This study will assess the safety and tolerability of AZD0530 in patients with Alzheimer's disease.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG saracatinib
Study Locations (1)
Connecticut
- Yale Alzheimer's Disease Research Unit - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2013-07 |
| Est. Completion | 2014-11-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01864655
The ClinicalTrials.gov registry entry for NCT01864655 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,061-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (99% lower). The listed sponsor is Stephen M. Strittmatter, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alzheimers Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01864655 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT01864655 about?
NCT01864655 is a clinical study titled "Safety and Tolerability of AZD0530 (Saracatinib) in Alzheimer's Disease". Alzheimer's disease is a devastating neurodegenerative disorder, for which there is currently no effective treatment to slow or halt progression. Beta amyloid peptide accumulates in the brains of those with Alzheimer's, and is thought to play a major role in triggering the dementia. The investigator...
What is the current status of trial NCT01864655?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2013-07. Estimated completion is 2014-11-06.
What conditions does trial NCT01864655 study?
This clinical trial studies the following conditions: Alzheimers Disease.
What interventions are being tested in trial NCT01864655?
The interventions under investigation include: Placebo (DRUG), saracatinib (DRUG).
Who is sponsoring clinical trial NCT01864655?
This trial is sponsored by Stephen M. Strittmatter, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01864655 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimers Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
RECRUITING · Phase 1
-
Safety and Target Engagement of Centella Asiatica in Cognitive Impairment
RECRUITING · Phase 1
-
A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)
RECRUITING · Phase 1
-
PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases
RECRUITING · Phase 1
-
A Clinical Trial of AAV2-BDNF Gene Therapy in Early Alzheimer's Disease and Mild Cognitive Impairment
RECRUITING · Phase 1
-
TREAD: Time Restricted Eating Intervention for Alzheimer's Disease
RECRUITING · Phase 1
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.